Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • plabaj
    Member
    • Oct 2010
    • 95

    MetaSUB Inter-City Challenge - CAMDA@ISMB/ECCB

    Founded in 2015, the MetaSUB International Consortium aims to create the world's only longitudinal metagenomic map of mass-transit systems and other public spaces across the globe. While Global City Sampling Day covered over 40 locations, the consortium has partnered with CAMDA for the first-ever multi-city analysis, with an early release of New York City, Boston, and Sacramento exclusive to MetaSUB and CAMDA.

    Analysis suggestions:
    • Biological: Compare organism fingerprints from public places across cities. Investigate organism sequences and biodiversity vs location. How diverse is each city – in terms of the numbers of bacteria, eukaryotes, viruses, plasmids, and antimicrobial resistance markers (AMRs)? Can we determine if each city has a distinct AMR profile?
    • Technical: Which computational tools have the highest sensitivity and specificity for species detection?


    Check also other CAMDA challenges!

    Join us for a stimulating scientific meeting and lively discussions in Prague 22-23 July 2017!

    Follow us on twitter @CAMDA_conf

    See you in Prague!
    Pawel Labaj
  • plabaj
    Member
    • Oct 2010
    • 95

    #2
    Submission Options

    There are two Submission Options:
    • Full methods research papers can be submitted to the regular ISMB Proceedings Track (note 26th of January ISMB Proceedings deadline!), specifying CAMDA as intended target audience.
    • Extended abstracts of late breaking methods research or analyses of the CAMDA challenge data sets can be submitted by the CAMDA submission deadline in May. Extended abstracts should include at least preliminary key results and figures. Based on the extended abstract, the scientific committee selects teams to present their work at the CAMDA conference, where updated results need to be shown.


    Check also other CAMDA challenges!

    Join us for a stimulating scientific meeting and lively discussions in Prague 22-23 July 2017!

    Follow us on twitter @CAMDA_conf

    See you in Prague!
    Pawel Labaj

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Yesterday, 11:41 AM
    0 responses
    10 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    23 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    37 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-09-2026, 10:04 AM
    0 responses
    45 views
    0 reactions
    Last Post SEQadmin2  
    Working...